International Stem Cell Corporation (OTCBB:ISCOE) announced today that
Donna Queen has joined ISCO's executive team. Ms. Queen will be
primarily responsible for ISCO's wholly owned subsidiary Lifeline Skin
Care's (Lifeline) brand identity and international marketing as well as
broadening the range of Lifeline products currently available.
Prior to joining ISCO, Ms. Queen was President and CEO of ZO SKIN
HEALTH® by Zein Obagi, MD. Dr. Obagi is the dermatologist who created
the original Obagi Nu-Derm skincare system, which has since become the
leading physician-dispensed brand of anti-aging skincare. Earlier Ms.
Queen founded and led one of Virginia's largest advertising and
marketing agencies, specializing in aesthetic and dermatological
marketing and brand development.
Dr. Andrey Semechkin, President and CEO of ISCO, commented: "I'm very
pleased that Ms. Queen has joined our team. Ms. Queen's industry
experience and expertise particularly in marketing prescription-based
products will be invaluable as we expand our skin care business and
further enhance our line of products."
Ms. Queen adds, "I'm very excited to be joining such a dynamic,
science-driven company. There have been no recent meaningful
technological breakthroughs in skin care, but with ISCO's scientific
leadership in stem cells and their knowledge of skin tissue physiology
we have an opportunity to continue to deliver new and innovative
treatments."
ISCO previously announced sales of approximately $1.1 million from the
pilot direct-to-consumer launch of Lifeline's first two products, an
anti-aging Day Serum and a Night Serum. These products were developed by
ISCO's scientific research team in collaboration with internationally
recognized cosmetics experts. The serums contain an extract from ISCOʽs
proprietary human parthenogenetic stem cells combined with antioxidants
and botanically derived ingredients. Using these serums on a regular
basis provides significant benefits to the skin including improvement in
skin tone and elasticity and the improvement in the appearance of fine
lines and wrinkles, results that have been independently established by
clinical studies performed at industry-leading testing laboratories. The
serums can be purchased by visiting Lifelineʽs website at www.lifelineskincare.com
and are also available at selected luxury spas and physicians' offices
in the United States.
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic
applications of human parthenogenetic stem cells and the development and
commercialization of cell-based research and cosmetic products. ISCO's
core technology, parthenogenesis, results in the creation of pluripotent
human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical
issues associated with the use or destruction of viable human embryos.
ISCO scientists have created the first parthenogenic, homozygous stem
cell line that can be a source of therapeutic cells with minimal immune
rejection after transplantation into hundreds of millions of individuals
of differing genders, ages and racial background. This offers the
potential to create the first true stem cell bank, UniStemCell™. ISCO
also produces and markets specialized cells and growth media for
therapeutic research worldwide through its subsidiary Lifeline Cell
Technology, and cell-based skin care products through its subsidiary
Lifeline Skin Care. More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click
on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-looking Statements
Statements pertaining to anticipated developments, product development
and marketing plans, and other opportunities for the company and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, competition, regulatory
approvals, need and ability to obtain future capital, application of
capital resources among competing uses, and maintenance of intellectual
property rights. Actual results may differ materially from the results
anticipated in these forward-looking statements and as such should be
evaluated together with the many uncertainties that affect the company's
business, particularly those mentioned in the cautionary statements
found in the company's Securities and Exchange Commission filings. The
company disclaims any intent or obligation to update forward-looking
statements.
International Stem Cell Corporation 760-940-6383 Ruslan
Semechkin, PhD Vice President, ISCO CEO, Lifeline Skin Care ras@intlstemcell.com or Simon
Craw, PhD Vice President, ISCO sc@intlstemcell.com or Lippert/Heilshorn
& Associates Don Markley 310-691-7100 dmarkley@lhai.com |